Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients

被引：1

作者：

Kraeber-Bodere, Francoise ^{[1
]}

Maisonneuve, Herve ^{[2
]}

Lamy, Thierry ^{[3
]}

Le Gouill, Steven ^{[4
]}

Deconninck, Eric ^{[5
]}

Pallardy, Amandine ^{[1
]}

Bodet-Milin, Caroline ^{[1
]}

Milpied, Noel ^{[6
]}

Morineau, Nadine ^{[7
]}

Foussard, Charles ^{[8
]}

Gastinne, Thomas ^{[4
]}

Gressin, Remy ^{[9
]}

Toumilhac, Olivier ^{[10
]}

Gyan, Emmanuel ^{[11
]}

Moreau, Anne

Chauvet, Alain Faivre ^{[1
]}

Cazeau, Anne-Laure ^{[12
]}

Garin, Etienne

Vuillez, Jean-Philippe ^{[13
]}

Chatal, Jean-Francois ^{[14
]}

Harousseau, Jean-Luc ^{[15
]}

Moreau, Philippe ^{[4
]}

Wegener, William ^{[16
]}

Goldenberg, David ^{[17
]}

Soubeyran, Pierre ^{[18
]}

机构：

[1] CHU Nantes, Nucl Med Serv, F-44035 Nantes 01, France

[2] CH La Roche Yon, La Roche Sur Yon, France

[3] CHU Rennes, Hematol Dept, Rennes, France

[4] CHU Nantes, Hematol Dept, F-44035 Nantes 01, France

[5] Hop Jean Minjoz, F-25030 Besancon, France

[6] Hop Haut Leveque, Pessac, France

[7] Ctr Catherine Sienne, Nantes, France

[8] CHU Angers, Serv Malad Sang, Angers, France

[9] CHU Grenoble, INSERM, Inst Albert Bonniot, U823, F-38043 Grenoble, France

[10] CHU Clermont Ferrand, Serv Hematol Adultes & Therapie Cellulaire, Clermont Ferrand, France

[11] CHRU Tours, Serv Hematol & Therapie Cellulaire, Tours, France

[12] Inst Bergonie, Nucl Med Serv, Bordeaux, France

[13] CHU Michallon, Nucl Med Serv, Grenoble, France

[14] GIP ARRONAX, St Herblain, France

[15] Rene Gauducheau Canc Ctr, St Herblain, France

[16] Immunomed Inc, Clin Res, Morris Plains, NJ USA

[17] Ctr Mol Med & Immunol, Belleville, NJ USA

[18] Inst Bergonie, Bordeaux, France

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

10.1182/blood.V116.21.2875.2875

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1184 / 1184

页数：1

共 48 条

[21] Interim results of a phase I/II radioimmunotherapy trial in relapsed/refractory non-Hodgkin's lymphoma (NHL) patients given 90Y-labeled anti-CD22 humanized monoclonal antibody, epratuzumab.
Hajjar, G
Sharkey, RM
Burton, J
Schuster, S
Czuczman, M
Lamonica, D
Chatal, JF
Alavi, A
Stadtmauer, EA
Leonard, J
Coleman, M
Plutchock, J
Brenner, AI
Goldenberg, DM
BLOOD, 2001, 98 (11) : 611A - 611A
[22] Phase 1 Dose-Escalation Study of 90yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Chevallier, Patrice
Eugene, Thomas
Robillard, Nelly
Isnard, Francoise
Nicolini, Franck E.
Escoffre-Barbe, Martine
Huguet, Francoise
Hunault, Mathilde
Marcais, Antoine
Guillaume, Thierry
Delaunay, Jacques
Peterlin, Pierre
Thomas, Xavier
Ifrah, Norbert
Lapusan, Simona
Bodet-Milin, Caroline
Chauvet, Alain Faivre
Le Houerou, Claire
Goldenberg, David M.
Wegener, William A.
Kraeber-Bodere, Francoise
BLOOD, 2014, 124 (21)
[23] Phase II study of sequential R-CHOP plus yttriurn 90 ibritumomab tiuxetan as first-line therapy for elderly patients at high risk with DLBCL
Reddy, GK
CLINICAL LYMPHOMA & MYELOMA, 2006, 6 (04): : 267 - 268
[24] A Phase II Trial of Rituximab-CHOP Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (90Y-IT) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients
Zinzani, Pier Luigi
Fina, Mariapaola
Tani, Monica
Stefoni, Vittorio
Gandolfi, Letizia
Broccoli, Alessandro
Pellegrini, Cinzia
Derenzini, Enrico
Rossi, Giuseppe
Angelucci, Emanuele
Gaidano, Gianluca
Petti, Maria Concetta
Martelli, Maurizio
Vitolo, Umberto
Fanti, Stefano
Baccarani, Michele
BLOOD, 2009, 114 (22) : 1065 - 1065
[25] Combination Anti-PD1 Antibody and Rituximab Followed By R-CHOP for Elderly Patients with Newly Diagnosed DLBCL: Analysis of the Phase II TREND Trial
Yan, Gao
Wang, Xiaoxiao
Bai, Bing
Li, Xue-Ping
Lin, Suxia
He, Yanxia
Ping, Liqin
Huang, Cheng
Li, Jibin
Mao, Jiaying
Huang, Huiqiang
BLOOD, 2022, 140 : 3737 - 3738
[26] A phase II trial of CHOP chemotherapy followed by Yttrium 90 (90Y) ibriturnomab tiuxetan (Zevalin®) for previously untreated elderly diffuse large B-Cell lymphoma (DLBCL) patients.
Zinzani, Pier Luigi
Tani, Monica
Fanti, Stefano
Stefoni, Vittorio
Musuraca, Gerardo
Castellucci, Paolo
Marchi, Enrica
Fina, Mariapaola
Baccarani, Michele
BLOOD, 2006, 108 (11) : 688A - 688A
[27] Early safety and efficacy analysis of a phase II study of sequential R-CHOP and Yttrium-90 ibritumomab tiuxetan (Zevalin®) for elderly high risk patients with untreated DLBCL
Hamlin, PA
Moskowitz, CH
Wegner, BC
Portlock, CS
Straus, DJ
Noy, A
Dumitrescu, O
Palomba, ML
Horwitz, SM
O'Connor, OA
Pandit-Taskar, N
Divgi, C
Zelenetz, AD
BLOOD, 2005, 106 (11) : 272A - 272A
[28] Anti-infective prophylaxis with aciclovir and cotrimoxazole to reduce the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy.
Murawski, Niels
Miriam, Josif
Altmann, Bettina
Ziepert, Marita
Haenel, Mathias
Viardot, Andreas
Neubauer, Andreas
Held, Gerhard
Truemper, Lorenz
Schmidt, Christian
Kanz, Lothar
Hallek, Michael
Schmitz, Norbert
Heintges, Tobias
Koelbel, Christian
Poeschel, Viola
Pfreundschuh, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[29] Anti-infective prophylaxis with aciclovir and cotrimoxazole significantly reduces the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy
Murawski, N.
Amam, J.
Altmann, B.
Ziepert, M.
Haenel, M.
Viardot, A.
Neubauer, A.
Held, G.
Truemper, L.
Schmidt, C.
Kanz, L.
Hallek, M.
Schmitz, N.
Heintges, T.
Koelbel, C.
Poeschel, V.
Pfreundschuh, M.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 11 - 11
[30] Weekly Four Times Rituximab Consolidation Following Reduced Cycles Of R-CHOP Induction Chemotherapy In Extremely Elderly Patients With Diffuse Large B Cell Lymphoma
Yang, Deok-Hwan
Kim, Won Seog
Do, Young-Rok
Oh, Sung Yong
Kim, Min Kyoung
Mun, Yeung-Chul
Shin, Ho-Jin
Kwak, Jae-Yong
Kang, Hye Jin
Won, Jong-Ho
Kwon, Jung Hye
Kim, Hyo Jung
Suh, Cheolwon
Lee, Je-Jung
BLOOD, 2013, 122 (21)

← 1 2 3 4 5 →